Pulmonary function, inflammation, exercise capacity and quality of life in cystic fibrosis

This study examined to what extent treatment-induced changes in exercise capacity and QoL were related to spirometric measures of lung function and other measures of disease impairment in 20 cystic fibrosis patients admitted to hospital with an exacerbation of pulmonary disease. Measures of disease impairment included FEV1, which was evaluated using the Vitalograph Alpha spirometer.